Biotech: Page


  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Roche, Dualitas team up to find bispecific drugs for immune diseases

    Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments. 

    By • Sept. 17, 2026
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis to pay $125M for blood-brain barrier crossing platform

    Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

    By • Sept. 16, 2026
  • Explore the Trendline➔
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • eye
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Sling banks $123M for an experimental thyroid eye disease pill

    A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

    By • Sept. 16, 2026
  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Skyhawk racks up more support for Huntington’s drug

    The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

    By • Sept. 16, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA clears first generic radioligand drug; Sionna turns to layoffs

    A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

    By BioPharma Dive staff • Sept. 15, 2026
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree

    RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.

    By • Sept. 11, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

    Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.

    By BioPharma Dive staff • Sept. 11, 2026
  • A stylized illustration of the human urinary system with the bladder highlighted.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tyra disappoints investors with bladder cancer data

    Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

    By • Sept. 9, 2026
  • A person in a white sweater holds a drug injection pen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Kura spins diabetes work into a Lilly-backed biotech startup

    Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

    By • Sept. 9, 2026
  • An illustration of pain in the colon.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    A new immuno-oncology play raises $225M for a next-generation drug

    Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.

    By • Sept. 9, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

    One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.

    By • Sept. 8, 2026
  • A photo of Moonwalk Biosciences' executive team.
    Image attribution tooltip
    Permission granted by Erin Beach
    Image attribution tooltip
    Obesity drugs

    Moonwalk reloads with $70M and new RNAi prospects for obesity

    The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

    By • Sept. 8, 2026
  • An exterior photo of Seattle Children's Hospital.
    Image attribution tooltip
    Courtesy of Seattle Children's Hospital
    Image attribution tooltip

    BrainChild hauls in $116M to make cell therapies for childhood brain cancers

    Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.

    By • Sept. 8, 2026
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: China deals, stock flatlines and Lilly’s M&A spree

    Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.

    By • Sept. 4, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

    Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

    By BioPharma Dive staff • Sept. 4, 2026
  • An illustration of dopamine outside the cell binding to a receptor.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    An AI drug specialist zeroes in on rare forms of obesity

    Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.

    By • Sept. 3, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    GSK wagers up to $1.3B on a different kind of cancer drug

    With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

    By • Sept. 3, 2026
  • An illustration of two immune checkpoint proteins binding
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Akeso, Summit cancer drug confirms lung cancer survival benefit

    A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

    By • Sept. 3, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

    Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

    By BioPharma Dive staff • Sept. 2, 2026
  • graphic image
    Image attribution tooltip
    Permission granted by Verily Health
    Image attribution tooltip
    Sponsored by Verily Health

    The next frontier: Advancing foundation models with multimodal data

    What's possible when AI models can learn from additional health data modalities to create a more complete understanding of human health?

    Aug. 31, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines

    Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.

    By BioPharma Dive staff • Aug. 28, 2026
  • Heart
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

    Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

    By • Aug. 28, 2026
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: Biotech’s rebound is undeniable

    Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

    By • Aug. 28, 2026
  • A bottle of brepocitinib, also known as Lisraya, Priovant's drug to treat the rare skin disease dermatomyositis.
    Image attribution tooltip
    Courtesy of Priovant Therapeutics
    Image attribution tooltip

    FDA green lights Priovant drug for rare skin disease

    Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

    By • Updated Aug. 28, 2026
  • A headshot of Michael Polansky, co-founder and CEO of Outer Bio
    Image attribution tooltip
    Permission granted by Outer Bio
    Image attribution tooltip
    Q&A // Emerging biotech

    Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.

    Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.

    By • Aug. 27, 2026